MindBio Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Public

  • Employees
  • 18

Employees

  • Stock Symbol
  • MBIO

Stock Symbol

  • Share Price
  • $0.06
  • (As of Monday Closing)

MindBio Therapeutics General Information

Description

MindBio Therapeutics Corp is engaged in the research, development, and testing of psychedelic substances as potential treatments for a broad range of mental health conditions. The Company also invests in research to develop treatments for conditions such as depression, anxiety, PTSD, and chronic pain. Its segment mainly relates to pharmaceutical research and development activities. The Company operates in the Australasia region.

Contact Information

Formerly Known As
1286409 B.C.
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Level 4, 91-97 William Street
  • Melbourne, Victoria 3000
  • Australia
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
CNQ
Corporate Office
  • Level 4, 91-97 William Street
  • Melbourne, Victoria 3000
  • Australia

MindBio Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MindBio Therapeutics Stock Performance

As of 16-Nov-2026, MindBio Therapeutics’s stock price is $0.06. Its current market cap is $408K with 7.28M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.06 $0.07 $0.05 - $2.85 $408K 7.28M 18.4K -$3.73

MindBio Therapeutics Financials Summary

As of 31-Mar-2026, MindBio Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 31-Mar-2026 FY 2025 30-Jun-2025 FY 2024 30-Jun-2024 FY 2023 30-Jun-2023
EV 5,462 3,874 6,943 10,004
Revenue 0 0 0 0
EBITDA (4,527) (1,440) (37) (2,578)
Net Income (4,702) (1,816) (269) (2,882)
Total Assets 814 76 130 445
Total Debt 1,533 1,463 3,326 3,291
Public Fundamental Data provided by Morningstar, Inc. disclaimer

MindBio Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore MindBio Therapeutics‘s full profile, request access.

Request a free trial

MindBio Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
MindBio Therapeutics Corp is engaged in the research, development, and testing of psychedelic substances as potential tr
Drug Discovery
Melbourne, Australia
18 As of 2023

New York, NY
 

Altrincham, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

MindBio Therapeutics Competitors (2)

One of MindBio Therapeutics’s 2 competitors is AtaiBeckley, a Formerly VC-backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AtaiBeckley Formerly VC-backed New York, NY
COMPASS Pathways Formerly VC-backed Altrincham, United Kingdom
You’re viewing 2 of 2 competitors. Get the full list »

MindBio Therapeutics Patents

MindBio Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2026903997-A0 Detection of neurologically active substances and fatigue in a human by analysis of voice characteristics Pending 28-Apr-2026

MindBio Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MindBio Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view MindBio Therapeutics’s complete esg history, request access »

MindBio Therapeutics FAQs

  • When was MindBio Therapeutics founded?

    MindBio Therapeutics was founded in 2021.

  • Where is MindBio Therapeutics headquartered?

    MindBio Therapeutics is headquartered in Melbourne, Australia.

  • What is the size of MindBio Therapeutics?

    MindBio Therapeutics has 18 total employees.

  • What industry is MindBio Therapeutics in?

    MindBio Therapeutics’s primary industry is Drug Discovery.

  • Is MindBio Therapeutics a private or public company?

    MindBio Therapeutics is a Public company.

  • What is MindBio Therapeutics’s stock symbol?

    The ticker symbol for MindBio Therapeutics is MBIO.

  • What is the current stock price of MindBio Therapeutics?

    As of 16-Nov-2026 the stock price of MindBio Therapeutics is $0.06.

  • What is the current market cap of MindBio Therapeutics?

    The current market capitalization of MindBio Therapeutics is $408K.

  • Who are MindBio Therapeutics’s competitors?

    AtaiBeckley and COMPASS Pathways are competitors of MindBio Therapeutics.

  • What is MindBio Therapeutics’s annual earnings per share (EPS)?

    MindBio Therapeutics’s EPS for 12 months was -$3.73.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process